Skip to main content
Lydia Visser

My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.

B Cells as Prognostic Biomarker After Surgery for Colorectal Liver Metastases
Published in: Frontiers in Oncology
Background: The aim of this study was to identify more accurate variables to improve prognostication of individual patients with colorectal liver metastases (CRLM). Clinicopathological characteristics only partly explain the large range in survival rates. Methods: MessengerRNA expression profiles of resected CRLM of two patient groups were analysed by mRNA sequencing: poor survivors (death from recurrent disease <30 months after surgery) and good survivors (no recurrent disease >60 months after surgery). Tumour and adjacent liver parenchyma samples were analysed. Results: MessengerRNA expression profiling of the tumour samples identified 77...
Joost Hof, Lydia Visser, Diederik J Höppener, Pieter M H Nierop, Miente M Terpstra, Annette S H Gouw, Dirk J Grünhagen, Cornelis Verhoef, Rolf H Sijmons, Koert P de Jong, Klaas Kok
Microenvironment, cross-talk, and immune escape mechanisms
Published in: Hematologic Malignancies
Hodgkin lymphoma is a unique malignancy in which reactive immune cells vastly outnumber the tumor cells. The microenvironment is essential in many different aspects of Hodgkin lymphoma biology and has ramifications for diagnosis, clinical presentation, and therapeutic options. In this chapter we review current knowledge on the Hodgkin lymphoma microenvironment. Its composition is highly variable and provides the basis for diagnostic subtyping. T cells are virtually always present and usually cluster together with the tumor cells in so-called rosettes. We describe mechanisms by which the tumor cells actively...
Lydia Visser, Johanna Veldman, Sibrand Poppema, Anke van den Berg, Arjan Diepstra
WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma
Published in: Therapeutic advances in hematology
Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, characterized by high levels of genomic instability and the activation of DNA damage repair pathways. We previously found high expression of the cell cycle regulator WEE1 in DLBCL cell lines. Here, we investigated the combination of the WEE1 inhibitor, AZD1775, with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) and radiation therapy (RT), with the aim of improving first-line treatment. Methods: Cell viability experiments were performed to determine synergistic combinations. Levels of DNA damage were established using flow cytometry for...
Mathilde R. W. de Jong, Myra Langendonk, Bart Reitsma, Pien Herbers, Monique Lodewijk, Marcel Nijland, Anke van den Berg, Emanuele Ammatuna, Lydia Visser, Tom van Meerten
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Hodgkin lymphoma is a B cell derived malignancy characterized by a low number of tumor cells within an environment consisting of inflammatory cells. Recently, immune checkpoint blockade targeting the PD-1-PD-L1 axis has shown to be a great success in relapsed and refractory Hodgkin lymphoma patients. However, complete responses are scarce and median progression-free survival is limited to around 11-15 months. Efficiency of PD-1 blockade in HL might be dependent on CD4 + T cells, but also tumor associated macrophages (TAMs) and NK cells are implicated. The aim of...
Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma
Published in: International Journal of Molecular Sciences
Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with diffuse large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy with cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP). Although studies focus mainly on the contribution of BCL-2, here we also investigate the contribution of other anti-apoptotic proteins to CHOP-therapy resistance in DLBCL. Functional dynamic BCL-2 homology (BH)3 profiling was applied to DLBCL cell lines upon CHOP treatment or single CHOP compounds. Cell-specific anti-apoptotic dependencies were validated with corresponding BH3-mimetics. We found high expression of...
Mathilde Rikje Willemijn de Jong, Myra Langendonk, Bart Reitsma, Marcel Nijland, Anke van den Berg, Emanuele Ammatuna, Lydia Visser, Tom van Meerten